Sorafenib

目录号:S7397 别名: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格 价格 库存 购买数量  
RMB 1205.41 现货
RMB 2214.52 现货
RMB 5503.41 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献63篇:

客户使用该产品的9个实验数据:

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

  • (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。
靶点
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性,IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1),mVEGFR3,mPDGFRβ,Flt3,和c-Kit,IC50分别为15 nM,20 nM,57 nM,58 nM,和68 nM。Sorafenib 能够较弱地抑制FGFR-1,IC50 为580 nM。Sorafenib对ERK-1,MEK-1,EGFR,HER-2,IGFR-1,c-Met,PKB,PKA,cdk1/cyclinB,PKCα,PKCγ,和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化,IC50 为 30 nM,也会抑制HEK-293细胞中Flt-3磷酸化,IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化,但不阻断A549 或 H460细胞中该过程,同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖,IC50分别为0.28 μM 和 2.6 μM。[1]除了抑制RAF/MEK/ERK信号通路,Sorafenib tosylate显著抑制eIF4E的磷酸化作用,并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖,IC50分别为6.3 μM 和 4.5 μM,并诱导显著的细胞凋亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMECwNFA{ODNizszN MWjTRW5ITVJ?
MONO-MAC-6 M1rhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDlUY1KSzVyPUCuNFA1OThizszN MnLUV2FPT0WU
ALL-PO NVz6OY04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTxbWNtUUN3ME2wMlA{OTh2IN88US=> M4\h[nNCVkeHUh?=
NKM-1 NXS1VopOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEe0NVYh|ryP M{TkOXNCVkeHUh?=
CGTH-W-1 NIHFVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXzTWM2OD1yLkK1NFIzKM7:TR?= MYXTRW5ITVJ?
BB65-RCC NUezW5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3UTWM2OD1yLkS3NFc{KM7:TR?= M1f3fXNCVkeHUh?=
NOS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNU[zOkDPxE1? MUTTRW5ITVJ?
SH-4 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jM[2lEPTB;MD62OVYyOyEQvF2= M{PiW3NCVkeHUh?=
HOP-62 NWjjdHJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwOEWwPFgh|ryP MlHDV2FPT0WU
HCC2998 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m3XWlEPTB;MD64PFgyQCEQvF2= NImxXm5USU6JRWK=
GDM-1 NGjCSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD1yLkmwOlk5KM7:TR?= M{G0S3NCVkeHUh?=
KM12 M1fIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6TWM2OD1zLkCyNFk5KM7:TR?= MmfCV2FPT0WU
LB2518-MEL NHj3W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmOGJKSzVyPUGuNlA5ODlizszN MYrTRW5ITVJ?
NCI-H1436 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jROGlEPTB;MT6yNVY4QCEQvF2= MV7TRW5ITVJ?
EM-2 NUPESJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO1XJpKSzVyPUGuN|U2PzhizszN M3\NOXNCVkeHUh?=
LAMA-84 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwM{e2OFgh|ryP M2T1[XNCVkeHUh?=
KG-1 NGnoVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rxXGlEPTB;MT60O|k{PSEQvF2= MXrTRW5ITVJ?
A388 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz0dGpIUUN3ME2xMlU6OTZ3IN88US=> MlzuV2FPT0WU
no-10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TiPWlEPTB;MT62NVczPiEQvF2= M3Pqd3NCVkeHUh?=
SF126 NH3iPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Sze2lEPTB;MT62N|gyOiEQvF2= NV3PXGtnW0GQR1XS
MEG-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn5XlBCUUN3ME2xMlgxQThizszN NYPiN41kW0GQR1XS
A3-KAW MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLhT5Z1UUN3ME2xMlg5PDJizszN NXfvcG8xW0GQR1XS
D-247MG NWT3TpZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDqTWM2OD1{LkG0OFgh|ryP NXzicVh6W0GQR1XS
OVCAR-4 NH7zWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPNSYRKSzVyPUKuNlE{QTNizszN MoDKV2FPT0WU
NCI-SNU-1 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwM{G2NkDPxE1? M{nIfHNCVkeHUh?=
NCI-H2171 NV30PIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV70SFh5UUN3ME2yMlM6PzZ2IN88US=> NHXCdHVUSU6JRWK=
SIG-M5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q0e2lEPTB;Mj60NlI1OiEQvF2= NF;a[WxUSU6JRWK=
BE-13 NVzLT4I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrySYhKSzVyPUKuOlk3ODlizszN M3Lx[XNCVkeHUh?=
K052 NGDTNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTWZXBKSzVyPUKuO|Q3OTZizszN M4DBTXNCVkeHUh?=
L-540 NXrQTFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLdWlEPTB;Mj63OVc5QSEQvF2= M2LIc3NCVkeHUh?=
KMOE-2 NEDyb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInLfWVKSzVyPUKuPFE{PSEQvF2= NGPKSGRUSU6JRWK=
MFH-ino NFvnRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3eyc2lEPTB;Mj65NlE5PSEQvF2= MXjTRW5ITVJ?
HL-60 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH36[o1KSzVyPUOuNFYzQTlizszN M3LoSnNCVkeHUh?=
HCC2218 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnG[3JKSzVyPUOuNVIxODNizszN MVvTRW5ITVJ?
TE-5 NIjvWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\NcWlEPTB;Mz6xN|E3OiEQvF2= Mm\4V2FPT0WU
MZ1-PC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDUTWM2OD1|LkS3OVA6KM7:TR?= M1rOZnNCVkeHUh?=
MRK-nu-1 NWnXW2VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD1|Lk[xOFY5KM7:TR?= NEW3TVhUSU6JRWK=
MZ7-mel NFL1cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ieWlEPTB;Mz62OlA6QSEQvF2= NG\DOo1USU6JRWK=
BC-1 NUL6doNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjENlJKSzVyPUOuO|QxOiEQvF2= NXnNfWlLW0GQR1XS
ST486 M1WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\4cllXUUN3ME2zMlg{Pjd|IN88US=> MofRV2FPT0WU
KS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNwOEixPVgh|ryP NFL4cHRUSU6JRWK=
SK-NEP-1 NWD2PHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwMU[4NVUh|ryP MWHTRW5ITVJ?
BC-3 NF3hbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwMkOzPVEh|ryP MoLlV2FPT0WU
NCI-H1581 NFLhS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPienp1UUN3ME20MlI5Pzl6IN88US=> NV:2fXhDW0GQR1XS
MHH-PREB-1 NFW3WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXweWFSUUN3ME20MlQxPDh2IN88US=> M2PDSnNCVkeHUh?=
NOMO-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwNEi5NFUh|ryP MmfDV2FPT0WU
QIMR-WIL M3HaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXSGJKSzVyPUWuNFczQTRizszN MWXTRW5ITVJ?
SF539 M2TQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH3OphKSzVyPUWuNVMzOjdizszN NVrIbnpxW0GQR1XS
TE-12 NWTtNGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rJZmlEPTB;NT6yOFkzQSEQvF2= NWnqPZdDW0GQR1XS
NCI-H510A MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLd21yUUN3ME21MlQyPjh3IN88US=> MVjTRW5ITVJ?
JAR M{ni[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrpZnhKSzVyPUWuOVA5OjRizszN M4[5bXNCVkeHUh?=
no-11 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTVwN{O1Olgh|ryP NEfsW2dUSU6JRWK=
BV-173 NXLsZ5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;RWnVuUUN3ME21Mlk2Pjh{IN88US=> M4H2d3NCVkeHUh?=
SR MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqyfo9KSzVyPU[uNFA3PzhizszN MXPTRW5ITVJ?
MOLT-16 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLsTWM2OD14LkK1NlY3KM7:TR?= NVzzfHdjW0GQR1XS
MZ2-MEL NUToOJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfMNnVGUUN3ME22MlMyQDN7IN88US=> NUjYWY81W0GQR1XS
SW954 M4\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrDTHZLUUN3ME22MlQ2QDZ4IN88US=> M2X0fnNCVkeHUh?=
ML-2 NHHJbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnaTJAzUUN3ME22MlUzQDR7IN88US=> Mkj5V2FPT0WU
OCI-AML2 NUTielFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkizTWM2OD14Lk[xNFYzKM7:TR?= M4\leXNCVkeHUh?=
SIMA M3ziZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\q[mlEPTB;Nz6wNFExOSEQvF2= NVfLO295W0GQR1XS
DOHH-2 NYGyb|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTdwMEW2O|Yh|ryP MUXTRW5ITVJ?
697 M1jXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfBT3ZKSzVyPUeuNFU6QDlizszN MV\TRW5ITVJ?
NB1 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX3TWM2OD15LkSwOFA4KM7:TR?= NIDLZ5hUSU6JRWK=
D-392MG M4TKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j6eWlEPTB;Nz62NlY3OyEQvF2= NUXlOW4{W0GQR1XS
ES8 NWXSdFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPIfFFKSzVyPUeuO|Y2ODNizszN MkfSV2FPT0WU
RPMI-8226 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7He4hKSzVyPUeuPFQ2OTFizszN NXrpPGxDW0GQR1XS
IST-MEL1 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW2[IJYUUN3ME24MlQxODB{IN88US=> NELXPHlUSU6JRWK=
NB14 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzVY1KSzVyPUiuOlMyOzNizszN NH7KXpVUSU6JRWK=
HD-MY-Z NInLR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjFS3hKSzVyPUiuOlM4PDZizszN NXHPemt[W0GQR1XS
TE-10 M3zMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3mSGRKSzVyPUiuO|Y{PTNizszN M1OycXNCVkeHUh?=
LC-1F NUPLRXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXu[FFKSzVyPUmuNVA5OzRizszN NX[1T2d3W0GQR1XS
OS-RC-2 NF;LS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf1fodKSzVyPUmuNVEzPDNizszN NGryfZVUSU6JRWK=
NCI-SNU-16 M{\0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fLdWlEPTB;OT6yNVAzPiEQvF2= M2PxcnNCVkeHUh?=
SHP-77 NIjabVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD17LkexOlYzKM7:TR?= M3XITXNCVkeHUh?=
A4-Fuk M3\6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrSOIVOUUN3ME25Mlc2PjFizszN MVTTRW5ITVJ?
NB6 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XYdmlEPTB;OT63OlAzQSEQvF2= NFLudpJUSU6JRWK=
JiyoyeP-2003 M2C3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\UTWM2OD1zMD60O|Q2KM7:TR?= NYnlVHFvW0GQR1XS
DMS-114 M{L2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXCTWM2OD1zMD61OFQyKM7:TR?= M3vWZnNCVkeHUh?=
NB7 NVzwOJd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULXfZlMUUN3ME2xNE44PTJ4IN88US=> NISwe|FUSU6JRWK=
NCI-H747 M3W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLkGyNVYh|ryP NEHQVHZUSU6JRWK=
HH NVuwe5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW2eZdKSzVyPUGxMlM5PzZizszN NVLwdIJvW0GQR1XS
EW-18 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvB[YJrUUN3ME2xNU46ODR2IN88US=> M4O4c3NCVkeHUh?=
CHP-126 NUPNeIcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vFe2lEPTB;MUGuPVc{QCEQvF2= NV\qbHhiW0GQR1XS
NTERA-S-cl-D1 M2jFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXFOXhKSzVyPUGyMlAzPzhizszN NF7QUIhUSU6JRWK=
DEL NX;0TmdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjHTWM2OD1zMj6wPVg2KM7:TR?= MWrTRW5ITVJ?
LU-139 M2DNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzD[3hKSzVyPUGyMlU1OTNizszN NIXreGxUSU6JRWK=
P30-OHK NEfkcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXGTWM2OD1zMj61OFc6KM7:TR?= NHLJVWtUSU6JRWK=
NCI-H1522 NESxTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofzTWM2OD1zMj63OFYh|ryP NX;q[ZRPW0GQR1XS
NCI-H1299 NXKzUGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHvTWM2OD1zMz6yPVEyKM7:TR?= M36xSHNCVkeHUh?=
UACC-257 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF60RpBKSzVyPUGzMlUyOjZizszN NELJVXdUSU6JRWK=
Calu-6 M1rqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDmcJhqUUN3ME2xN{43ODR4IN88US=> MYfTRW5ITVJ?
NCI-H1882 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF|Lki1OVUh|ryP M2XtVHNCVkeHUh?=
BB30-HNC MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\QdGlEPTB;MUSuNFYxQSEQvF2= NV63Z4RpW0GQR1XS
ES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\KXGIxUUN3ME2xOE4yPTVzIN88US=> NITl[IxUSU6JRWK=
NCI-H1694 NYO5WIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nZVGlEPTB;MUSuOFgyOSEQvF2= MXLTRW5ITVJ?
IST-SL1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2Lkm2NVYh|ryP NXLy[JdQW0GQR1XS
ECC4 NGTN[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvETWM2OD1zNT6wOVU5KM7:TR?= MV3TRW5ITVJ?
MDA-MB-134-VI NUnHR2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXRfXlOUUN3ME2xOU41OTNzIN88US=> MkK3V2FPT0WU
SCH MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\FPFNZUUN3ME2xOU41PzJ6IN88US=> M1jYSXNCVkeHUh?=
SK-N-FI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HYR2lEPTB;MUWuOlU{PCEQvF2= NYPYbpVsW0GQR1XS
HDLM-2 M2\FRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2fGlKSzVyPUG2MlA4OTRizszN NH[w[G1USU6JRWK=
Ramos-2G6-4C10 M1i0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknhTWM2OD1zNj6xNlk4KM7:TR?= MkDPV2FPT0WU
EW-24 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jTXWlEPTB;MU[uNVY3OSEQvF2= NUjNTZZkW0GQR1XS
NCI-H2141 NWDLbYt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:2TWM2OD1zNj6xPFkh|ryP M33OSnNCVkeHUh?=
LC4-1 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT2dmZ4UUN3ME2xOk43OTF7IN88US=> NYDiN4lmW0GQR1XS
HT-144 NVXDV3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF5LkCwOkDPxE1? MmTNV2FPT0WU
SK-MEL-1 NIrsV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLVW2tJUUN3ME2xO{4xODd{IN88US=> NF30ZllUSU6JRWK=
SCC-15 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\jTJlKSzVyPUG3MlE3OzhizszN M4e5NnNCVkeHUh?=
C8166 NWD0[mJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjcXJ1UUN3ME2xO{43QDN|IN88US=> M2T2UXNCVkeHUh?=
GOTO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364dGlEPTB;MUeuPFM1PCEQvF2= NUnrd4ltW0GQR1XS
COR-L279 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvCTGlKSzVyPUG4MlE{PjJizszN M4fVUnNCVkeHUh?=
K-562 M{nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\1UmxIUUN3ME2xPE44OTR|IN88US=> MVXTRW5ITVJ?
ES3 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF6LkiwOFEh|ryP NH30e3BUSU6JRWK=
LU-165 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF7LkewNFgh|ryP MnfCV2FPT0WU
KM-H2 NFracGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7VTWM2OD1{MD6zNVg1KM7:TR?= MYfTRW5ITVJ?
RL Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJyLkm2PVIh|ryP NEi5dndUSU6JRWK=
EW-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizSWhKSzVyPUKxMlE5QDlizszN NXrsOpVOW0GQR1XS
A101D MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDoSGFKSzVyPUKxMlM4PTJizszN Mnv6V2FPT0WU
HUTU-80 NU\kNmtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfDUmlTUUN3ME2yNU4{QTR4IN88US=> M1fIOHNCVkeHUh?=
NCI-H23 NWnMUFBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTnTWM2OD1{MT6zPVkzKM7:TR?= MVfTRW5ITVJ?
PF-382 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXaTWM2OD1{MT60OFA{KM7:TR?= MnHxV2FPT0WU
LB373-MEL-D NWL3T2YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJzLkW2NVUh|ryP MlrFV2FPT0WU
TE-8 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP3TWM2OD1{MT62N|k1KM7:TR?= NFfWWJhUSU6JRWK=
TE-9 M1;yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJzLki1NVMh|ryP Mo\NV2FPT0WU
Daudi NWTkc5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDodHJFUUN3ME2yNU46OzB2IN88US=> NWKwUYg{W0GQR1XS
D-542MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDWXpRKSzVyPUKyMlAzPTZizszN MmDvV2FPT0WU
U-698-M NIXldmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ{LkS2NFMh|ryP MkDYV2FPT0WU
ES6 NVi3XmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ{LkezOlYh|ryP NW\MWVZ2W0GQR1XS
DU-4475 NWDYSIluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31WI5EUUN3ME2yN{45QDl5IN88US=> NXnGVIl[W0GQR1XS
ECC12 NUDaNVdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjpbZlKSzVyPUK0MlI5ODNizszN NWDTZoFpW0GQR1XS
C2BBe1 M3XhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVewZY1yUUN3ME2yOE4{OjN7IN88US=> MXHTRW5ITVJ?
IST-SL2 NVO5UmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;kc2xXUUN3ME2yOE41OzZ{IN88US=> M2TCWnNCVkeHUh?=
DJM-1 NVewV3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD1{ND61NlIyKM7:TR?= M3LXNnNCVkeHUh?=
DMS-153 NHrodJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ2Lki2NVQh|ryP M4C5PXNCVkeHUh?=
NB13 NVPrU4pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q3NGlEPTB;MkWuNFI3PSEQvF2= MmTYV2FPT0WU
SK-N-DZ NXq0TXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ4LkO0NVQh|ryP MVTTRW5ITVJ?
COR-L88 NF3DVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFNWlEPTB;Mk[uOVc6PiEQvF2= M3LYTnNCVkeHUh?=
LU-65 NIfaR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rVcGlEPTB;Mk[uPFU{PSEQvF2= M3KwVHNCVkeHUh?=
TGBC1TKB Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLqTWM2OD1{Nj65PFI5KM7:TR?= NX[5Z|dsW0GQR1XS
THP-1 NHvadXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ5LkKxOFEh|ryP NF;SPIdUSU6JRWK=
ONS-76 NGn5ZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnwV3BKSzVyPUK3MlM{OiEQvF2= MkPTV2FPT0WU
LC-2-ad MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ5Lk[yN|Eh|ryP MXvTRW5ITVJ?
EW-13 NVPrfZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD1{OT6xO|Q3KM7:TR?= MVLTRW5ITVJ?
MS-1 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNyLkeyO|gh|ryP Mln6V2FPT0WU
NCI-H2227 M4XMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3nZVRPUUN3ME2zNE46QDB4IN88US=> MXzTRW5ITVJ?
LXF-289 NVvpNJJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPnOopKSzVyPUOxMlQ1QTJizszN MUnTRW5ITVJ?
MC116 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ufWlEPTB;M{KuNFgzPiEQvF2= NFrMN4pUSU6JRWK=
EVSA-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP1W5lJUUN3ME2zNk4zPTh3IN88US=> MX3TRW5ITVJ?
CTB-1 NIL5fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWTWM2OD1|Mz6xNVAyKM7:TR?= MXvTRW5ITVJ?
COLO-320-HSR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjUb|dKSzVyPUOzMlE3ODNizszN MV;TRW5ITVJ?
NCI-H2196 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHnRnNKSzVyPUOzMlI2PTdizszN M3\KRXNCVkeHUh?=
LB2241-RCC NVTxRVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrXXJdnUUN3ME2zN{4{OTN3IN88US=> M3nwZXNCVkeHUh?=
LS-513 NEDmc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvtR5RrUUN3ME2zN{45PjN6IN88US=> MXTTRW5ITVJ?
LP-1 NITFRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;aRYJQUUN3ME2zN{46QTV4IN88US=> M4\JeXNCVkeHUh?=
A253 M{\iXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\uU2FKSzVyPUO0MlIzQTZizszN MVjTRW5ITVJ?
SK-MM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTj[4dYUUN3ME2zOE46PDVzIN88US=> NH6zdJVUSU6JRWK=
NCI-H1963 NYTK[WM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4TnI2UUN3ME2zOU4{ODd{IN88US=> MXHTRW5ITVJ?
MMAC-SF NF7QeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HtWWlEPTB;M{WuPFc5PSEQvF2= M2OzZnNCVkeHUh?=
LB831-BLC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle5TWM2OD1|Nj6wOlU1KM7:TR?= NILGXG5USU6JRWK=
WSU-NHL M1LGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2XmZKSzVyPUO2MlE3PCEQvF2= NWPrNXhEW0GQR1XS
CESS M{\UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7BTWM2OD1|Nj6yPFQ5KM7:TR?= NYLBboM2W0GQR1XS
NEC8 NYft[ld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi5O2lKSzVyPUO2MlU5OzVizszN MnXpV2FPT0WU
KNS-42 M2HQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1dWlEPTB;M{euNVI{PyEQvF2= NILPeGVUSU6JRWK=
MHH-CALL-2 NYXlPJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq5[|A2UUN3ME2zO{4yQDJzIN88US=> M3zWZXNCVkeHUh?=
K5 NUDWfJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXHcGFKSzVyPUO4MlQ{KM7:TR?= NU\VcpZHW0GQR1XS
CP66-MEL NGP2WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr2TWM2OD1|OT6wO|M{KM7:TR?= M{XvTnNCVkeHUh?=
OPM-2 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\KUWlEPTB;M{muPFQ{OiEQvF2= NWPrT48{W0GQR1XS
IST-MES1 NXraTnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zzbWlEPTB;NECuN|A6PiEQvF2= NG\UZmRUSU6JRWK=
EC-GI-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTYTWM2OD12MT61PFA2KM7:TR?= NE\COI5USU6JRWK=
CTV-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\aN4xNUUN3ME20Nk45PDB4IN88US=> NUfibIVOW0GQR1XS
DG-75 M2r4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqdmlEPTB;NEOuO|U6PSEQvF2= Mlz6V2FPT0WU
KNS-81-FD M3PSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR3LkSwOVgh|ryP MXHTRW5ITVJ?
NCI-H82 NUKweJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3OTWM2OD12NT61O|U5KM7:TR?= M1r0OHNCVkeHUh?=
RPMI-8866 NXnNPFRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpTWM2OD12Nj6xPFc{KM7:TR?= Mnz4V2FPT0WU
ACN NF7IeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7RTWM2OD12Nj60N|Qh|ryP MnPqV2FPT0WU
NCI-H1395 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn6WWFKUUN3ME20Ok41PzV4IN88US=> M{PXSHNCVkeHUh?=
NCI-H209 M1X5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke0TWM2OD12Nz6xOFA2KM7:TR?= MV3TRW5ITVJ?
TGW MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\pSpZKSzVyPUS5MlA4QTFizszN Mn71V2FPT0WU
NCI-H748 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR7LkS3OVMh|ryP NUf6bnkyW0GQR1XS
EKVX NHjtdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR7Lk[2Nlgh|ryP MlPWV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Sorafenib(~60 mg/kg)口服给药,对各种人肿瘤异种移植模型,包括MDA-MB-231,Colo-205,HT-29,DLD-1,NCI-H460,和A549表现出广谱的、剂量依赖性抗肿瘤活性,而没有毒性。与抗肿瘤功效相联系,Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平,但对Colo-205异种移植物没有作用,并且也能显著抑制MDA MB-231,HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。[1] 在SCID小鼠体内,Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制,10 mg/kg和30 mg/kg剂量下,TGIs分别为49%和78%,与ERK 和 eIF4E磷酸化抑制,微血管面积减少,和肿瘤细胞凋亡的诱导相一致。[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax-/-和HT29肿瘤异种移植物表现出显著的功效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

生化检测:

重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生,并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克),或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2),100 mM NaCl,5 mM MgCl2,和0.15% β-巯基乙醇]中,DMSO终浓度为1%。加入25微升10 μM γ[33P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升),并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集,使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后,使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达,并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下:1 到10 μM ATP,25 nM poly GT生物素,2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20),10 nM APC,1% DMSO 终浓度的1 到 7 nM 细胞质激酶域,50 mM HEPES (pH 7.5),10 mM MgCl2,0.1 mM EDTA,0.015% Brij-35,0.1 毫克/毫升BSA,和0.1% β-巯基乙醇。反应体积为100微升,加入酶启动反应。反应启动~1.5 到 2.0小时后,板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算:对每孔(665 nm/615 nM) × 10,000。对IC50的产生,在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验:[1]
+ 展开
  • Cell lines: MDA-MB-231,和 HAoSMC
  • Concentrations: 溶解于DMSO,终浓度为~10 μM
  • Incubation Time: 72小时
  • Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号,测量每孔中的活细胞。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 雌性 NCr-nu/nu 小鼠,皮下植入MDA-MB-231,Colo-205,HT-29,H460,或 A549 细胞
  • Formulation: 以4倍(4 ×储备溶液,稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50)
  • Dosages: ~60 mg/kg
  • Administration: 口服,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.82
化学式

C21H16ClF3N4O3

CAS号 284461-73-0
稳定性 powder
in solvent
别名 BAY 43-9006

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03468231 Recruiting Hepatocellular Carcinoma Sun Yat-sen University|First Affiliated Hospital Sun Yat-Sen University|Dongguan People''s Hospital|Kaiping Central Hospital|First Affiliated Hospital Xi''an Jiaotong University|Guangzhou Twelfth People ''s Hospital|The First Affiliated Hospital of University of South China March 9 2018 Phase 3
NCT02616692 Completed Hepatocellular Cancer Bayer May 9 2016 --
NCT01751763 Completed Carcinoma Hepatocellular Bayer July 9 2013 --
NCT02530476 Active not recruiting Leukemia|Acute Myeloid Leukemia M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc|National Cancer Institute (NCI) December 8 2015 Phase 1|Phase 2
NCT02303444 Active not recruiting Thyroid Neoplasms Bayer April 8 2015 --
NCT01258608 Completed Carcinoma Hepatocellular Human Genome Sciences Inc. a GSK Company|GlaxoSmithKline February 8 2011 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Sorafenib | Sorafenib供应商 | 采购Sorafenib | Sorafenib价格 | Sorafenib生产 | 订购Sorafenib | Sorafenib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID